 |
| About Bioline | All Journals | Testimonials | Membership | News |
|
||||||
|
||||||
Indian Journal of Dermatology, Venereology, Leprology, Vol. 69, No. 6, Nov-Dec, 2003, pp. 430 Letter To Editor Response by the authors Sharma AD, Gupte PD, Sundaram M, Janaki VR, Rege VL, Bilimoria FE, Arora J Wallace Pharmaceutical Ltd., Mumbai Code Number: dv030 Sir, Lincomycin, belonging to the group of lincosamides, has been in use for the past 40 years.[1] The incidence of resistance associated with the use of lincomycin is lower than with some other antibiotics.[2] Earlier in vitro studies have demonstrated the effect of lincomycin against Propionibacterium acnes,[3] the organism implicated in acne. Recent reports have suggested that P. acnes has developed resistance to a number of commonly used topical anti-acne agents.[4] The major aim of development of a topical formulation of lincomycin, the first of its kind, was to have a newer topical antibiotic to which the organism had not been earlier exposed. Lincomycin gel was therefore developed as a potent topical anti-acne agent. As it is an original formulation developed by Wallace Pharmaceuticals, acute and chronic toxicity studies were performed,[5] followed by a multicentric clinical study[6] to determine its efficacy. These have proved that the formulation was effective and well tolerated. As a topical formulation is available only in India recently, this has not been mentioned in textbooks. As regards its safety profile, the study compared lincomycin gel with the base used (placebo) and demonstrated that adverse effects with the active drug were no more than with the placebo. Further comparative studies with other available anti-acne agents should be useful in determining the comparative efficacy and tolerability of lincomycin gel. REFERENCES
Copyright 2003 - Indian Journal of Dermatology, Venereology, Leprology |
| |||||||||
